These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37269430)

  • 1. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations.
    Garcia-Salinas R; Sanchez-Prado E; Mareco J; Ronald P; Ruta S; Gomez R; Magri S
    Rheumatol Int; 2023 Oct; 43(10):1821-1828. PubMed ID: 37269430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and insights in managing difficult-to-treat rheumatoid arthritis: real-world clinical perspectives.
    Alp G; Cinakli H; Kurut Aysin İ; Solmaz D; Akar S
    Clin Exp Rheumatol; 2024 Jul; 42(7):1398-1406. PubMed ID: 38372714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients.
    Cincinelli G; Maioli G; Posio C; Favalli EG; Ingegnoli F; Caporali R
    Arthritis Res Ther; 2024 Sep; 26(1):161. PubMed ID: 39289770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study.
    Michitsuji T; Fukui S; Morimoto S; Endo Y; Nishino A; Nishihata S; Tsuji Y; Shimizu T; Umeda M; Sumiyoshi R; Koga T; Iwamoto N; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Ohtsubo H; Takaoka H; Hamada H; Tsuru T; Nawata M; Arinobu Y; Hidaka T; Tada Y; Kawakami A; Kawashiri SY
    Scand J Rheumatol; 2024 Mar; 53(2):123-129. PubMed ID: 38085537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat.
    Ekin A; Misirci S; Görünen A; Coskun BN; Yagiz B; Dalkilic E; Pehlivan Y
    Med Princ Pract; 2024 Sep; ():1-12. PubMed ID: 39288740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort.
    Watanabe R; Hashimoto M; Murata K; Murakami K; Tanaka M; Ohmura K; Ito H; Matsuda S
    Immunol Med; 2022 Mar; 45(1):35-44. PubMed ID: 34033729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].
    Galushko EA; Gordeev AV; Matyanova EV; Olyunin YA; Nasonov EL
    Ter Arkh; 2022 Jun; 94(5):661-666. PubMed ID: 36286966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
    Watanabe R; Ebina K; Gon T; Okano T; Murata K; Murakami K; Maeda Y; Jinno S; Shirasugi I; Son Y; Amuro H; Katayama M; Hara R; Hata K; Yoshikawa A; Yamamoto W; Tachibana S; Hayashi S; Etani Y; Katsushima M; Fukumoto K; Yamada S; Hashimoto M
    Rheumatology (Oxford); 2024 Sep; 63(9):2418-2426. PubMed ID: 38724245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
    Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
    Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study.
    Roodenrijs NMT; Welsing PMJ; van der Goes MC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
    Rheumatology (Oxford); 2021 Oct; 60(10):4681-4690. PubMed ID: 33502493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study.
    Qi W; Robert A; Singbo N; Ratelle L; Fortin PR; Bessette L; Brown JP; Michou L
    Adv Rheumatol; 2024 Aug; 64(1):55. PubMed ID: 39107865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACPA Antibodies Titer at the Time of Rheumatoid Arthritis Diagnosis Is Not Associated with Disease Severity.
    Shpatz R; Braun-Moscovici Y; Balbir-Gurman A
    Isr Med Assoc J; 2021 Oct; 23(10):646-650. PubMed ID: 34672447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease.
    Leon L; Madrid-Garcia A; Lopez-Viejo P; González-Álvaro I; Novella-Navarro M; Freites Nuñez D; Rosales Z; Fernandez-Gutierrez B; Abasolo L
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36889800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease.
    Roodenrijs NMT; van der Goes MC; Welsing PMJ; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
    Rheumatology (Oxford); 2021 Aug; 60(8):3778-3788. PubMed ID: 33331946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis.
    Su QY; Luo J; Zhang Y; Li Q; Jiang ZQ; Wen ZR; Wang YY; Shi MR; Zhang SX
    J Transl Med; 2024 Aug; 22(1):795. PubMed ID: 39198829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis.
    Anno S; Okano T; Mamoto K; Yamada Y; Mandai K; Orita K; Iida T; Tada M; Inui K; Koike T; Nakamura H
    Mod Rheumatol; 2024 Aug; ():. PubMed ID: 39215592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes.
    David P; Di Matteo A; Hen O; Dass S; Marzo-Ortega H; Wakefield RJ; Bissell LA; Nam J; Mankia K; Emery P; Saleem B; McGonagle D
    Arthritis Rheumatol; 2024 Apr; 76(4):510-521. PubMed ID: 38059326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.
    Conran C; Kolfenbach J; Kuhn K; Striebich C; Moreland L
    Curr Rheumatol Rep; 2023 Dec; 25(12):285-294. PubMed ID: 37776482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis.
    Takanashi S; Takeuchi T; Kaneko Y
    Rheumatology (Oxford); 2024 Jun; ():. PubMed ID: 38851883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.